Analysis of interfractional set-up errors and intrafractional organ motions during IMRT for head and neck tumors to define an appropriate planning target volume (PTV) …
M Suzuki, Y Nishimura, K Nakamatsu… - Radiotherapy and …, 2006 - Elsevier
BACKGROUND AND PURPOSE: To analyze the interfractional set-up errors and intrafractional
organ motions and to define appropriate planning target volume (PTV)- and planning …
organ motions and to define appropriate planning target volume (PTV)- and planning …
Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula
Y Nishimura, M Suzuki, K Nakamatsu… - International Journal of …, 2002 - Elsevier
Purpose: A prospective trial of concurrent chemoradiotherapy (CT-RT) with a protracted
infusion of 5-fluorouracil and cisplatin was performed to evaluate the safety and efficacy of this …
infusion of 5-fluorouracil and cisplatin was performed to evaluate the safety and efficacy of this …
[HTML][HTML] Evaluation of multiple institutions' models for knowledge-based planning of volumetric modulated arc therapy (VMAT) for prostate cancer
…, J Fukunaga, T Kamima, Y Adachi, K Nakamatsu… - Radiation …, 2018 - Springer
Background The aim of this study was to evaluate the performance of a commercial
knowledge-based planning system, in volumetric modulated arc therapy for prostate cancer at …
knowledge-based planning system, in volumetric modulated arc therapy for prostate cancer at …
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
…, H Okamoto, K Nakagawa, K Watanabe, K Nakamatsu… - Lung cancer, 2011 - Elsevier
INTRODUCTION: A feasibility study was performed to examine the safety and toxicity profile
of daily gefitinib (250mg) administration with concurrent definitive thoracic radiation therapy (…
of daily gefitinib (250mg) administration with concurrent definitive thoracic radiation therapy (…
Incidence and risk factors of symptomatic radiation pneumonitis in non–small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation …
…, N Araki, K Fujii, S Okumura, K Nakamatsu… - Clinical Lung Cancer, 2021 - Elsevier
Introduction Data on the risk factors for symptomatic radiation pneumonitis (RP) in non–small-cell
lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT) and …
lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT) and …
Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT
Y Nishimura, K Nakamatsu, T Shibata… - Japanese journal of …, 2005 - academic.oup.com
Objective: Our aim was to evaluate predictors of xerostomia in patients with head and neck
cancers treated with intensity-modulated radiation therapy (IMRT). Methods: Thirty-three …
cancers treated with intensity-modulated radiation therapy (IMRT). Methods: Thirty-three …
A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before …
…, T Shibata, S Kanamori, K Nakamatsu… - Journal of Radiation …, 2013 - academic.oup.com
To visualize intratumoral hypoxic areas and their reoxygenation before and during fractionated
radiation therapy (RT), 18 F-fluoromisonidazole positron emission tomography and …
radiation therapy (RT), 18 F-fluoromisonidazole positron emission tomography and …
Phase II study of neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable stage IIIA-B (discrete N2) …
A Hamada, J Soh, A Hata, K Nakamatsu… - Clinical Lung Cancer, 2021 - Elsevier
Introduction We describe our ongoing multicenter, prospective, single-arm, phase II trial of
neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgical resection and …
neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgical resection and …
Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
…, K Fujii, S Okumura, K Nakamatsu… - Journal of Radiation …, 2023 - academic.oup.com
Chemoradiotherapy followed by consolidation durvalumab (CCRT+D) improves survival in
patients with stage III non-small-cell lung cancer (NSCLC). We compared recurrence patterns …
patients with stage III non-small-cell lung cancer (NSCLC). We compared recurrence patterns …
[HTML][HTML] Mechanical performance of a commercial knowledge-based VMAT planning for prostate cancer
…, M Otsuka, M Inada, H Doi, K Ishikawa, K Nakamatsu… - Radiation …, 2018 - Springer
Background This study clarified the mechanical performance of volumetric modulated arc
therapy (VMAT) plans for prostate cancer generated with a commercial knowledge-based …
therapy (VMAT) plans for prostate cancer generated with a commercial knowledge-based …